Sorafenib alone versus Sorafenib combined with Gemcitabine and Oxaliplatin (GEMOX) in the first-line treatment of advanced hepatocellular carcinoma: final analysis of the randomized phase II GoNext trial (a UNICANCER/FFCD/PRODIGE 10 study)

被引：0
|
作者：
Assenat, E. [1 ]
Boige, V. [2 ]
Thezenas, S. [3 ]
Pageaux, G. P. [4 ]
Perron, J. M. [5 ]
Becouarn, Y. [6 ]
Seitz, J. F. [7 ]
Merle, P. H. [8 ]
Blanc, J. F. [9 ]
Ychou, M. [10 ]
机构：
[1] Univ Hosp Montpellier, Montpellier 05, France
[2] IGR Canc Ctr, Villejuif, France
[3] ICM Canc Ctr, Montpellier, France
[4] CHU St Eloi, Montpellier, France
[5] CHU, Toulouse, France
[6] Inst Bergonier, Bordeaux, France
[7] CHU La Timone, Marseille, France
[8] CHU, Lyon, France
[9] CHU St Andre, Bordeaux, France
[10] ICM Canc Ctr, Montpellier, France
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2467
引用
收藏
页码：S578 / S578
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma
    Shu, Yamin
    Tang, Ying
    Ding, Yufeng
    Zhang, Qilin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 122
  • [22] Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma A Phase 3 Randomized Clinical Trial
    Qin, Shukui
    Kudo, Masatoshi
    Meyer, Tim
    Bai, Yuxian
    Guo, Yabing
    Meng, Zhiqiang
    Satoh, Taroh
    Marino, Donatella
    Assenat, Eric
    Li, Songzi
    Chen, Yaxi
    Boisserie, Frederic
    Abdrashitov, Ramil
    Finn, Richard S.
    Vogel, Arndt
    Zhu, Andrew X.
    JAMA ONCOLOGY, 2023, 9 (12) : 1651 - 1659
  • [23] Global phase III study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC): A trial-in-progress
    Qin, S.
    Finn, R. S.
    Kudo, M.
    Meyer, T.
    Vogel, A.
    Ducreux, M. P.
    Macarulla, T. M.
    Tomasello, G.
    Boisserie, F.
    Hou, J.
    Li, C.
    Song, J.
    Zhu, A. X.
    ANNALS OF ONCOLOGY, 2018, 29
  • [24] Sorafenib plus Doxorubicin versus Sorafenib alone for advanced hepatocellular carcinoma (Soradox trial): final results of a prospective, randomized, open-label, multicenter phase IIb trial
    Ettrich, T.
    Perkofer, L.
    Berger, A. W.
    Guethle, M.
    Behl, S.
    Zipprich, A.
    Woerns, M. A.
    Waldschmidt, D. T.
    Belle, S.
    Michl, P.
    Seufferlein, T.
    Dollinger, M. M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S457 - S457
  • [25] Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis
    Zheng, Zhiwei
    Lin, Yuxuan
    Cai, Hongfu
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [26] Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis
    Luo, Jia
    Gao, Benjian
    Lin, Zhiyu
    Fan, Hua
    Ma, Wen
    Yu, Danfei
    Yang, Qian
    Tian, Jing
    Yang, Xiaoli
    Li, Bo
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [27] Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
    Ikeda, M.
    Shimizu, S.
    Sato, T.
    Morimoto, M.
    Kojima, Y.
    Inaba, Y.
    Hagihara, A.
    Kudo, M.
    Nakamori, S.
    Kaneko, S.
    Sugimoto, R.
    Tahara, T.
    Ohmura, T.
    Yasui, K.
    Sato, K.
    Ishii, H.
    Furuse, J.
    Okusaka, T.
    ANNALS OF ONCOLOGY, 2016, 27 (11) : 2090 - 2096
  • [28] Phase II study of sorafenib with gemcitabine and erlotinib (GES) in first-line advanced pancreatic cancer.
    Cohen, D. J.
    Leichman, L. P.
    Love, E.
    Ryan, T.
    Leichman, C. G.
    Newman, E.
    Levinson, B.
    Hochster, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [29] RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
    Qin, Shukui
    Finn, Richard S.
    Kudo, Masatoshi
    Meyer, Tim
    Vogel, Arndt
    Ducreux, Michel
    Macarulla, Teresa Mercade
    Tomasello, Gianluca
    Boisserie, Frederic
    Hou, Jeannie
    Li, Xin
    Song, James
    Zhu, Andrew X.
    FUTURE ONCOLOGY, 2019, 15 (16) : 1811 - 1822
  • [30] Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial
    Masaaki Kondo
    Manabu Morimoto
    Satoshi Kobayashi
    Shinichi Ohkawa
    Hisashi Hidaka
    Takahide Nakazawa
    Hiroshi Aikata
    Takeshi Hatanaka
    Daichi Takizawa
    Kotaro Matsunaga
    Chiaki Okuse
    Michihiro Suzuki
    Masataka Taguri
    Takako Ishibashi
    Kazushi Numata
    Shin Maeda
    Katsuaki Tanaka
    BMC Cancer, 19
12345